Physician profile
Samir Mullick
NPI 1568416220
$3,101.87
in general payments reported to CMS, 2019-2025
22 companies · $726 in 2025
The $726 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $107 · 2021: $399 · 2022: $400 · 2023: $489 · 2024: $601 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $564.59 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $433.60 | 2021-2025 | Qelbree, Qelbree |
| Seqirus USA INC | $397.76 | 2019-2025 | Flucelvax, Flucelvax Quadrivalent, Fluad |
| Merck Sharp & Dohme LLC | $305.29 | 2020-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ironshore Pharmaceuticals INC. | $261.91 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $246.42 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $180.72 | 2019-2023 | |
| Cranial Technologies, INC | $151.06 | 2020-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $89.20 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.58 | 2019-2022 | |
| Rhodes Pharmaceuticals L.P. | $64.59 | 2019 | |
| Adlon Therapeutics L.P. | $62.51 | 2021 | |
| Tris Pharma INC | $48.53 | 2024-2025 | Dyanavel Xr |
| Phadia US INC. | $47.66 | 2019-2024 | Immunocap |
| Ultragenyx Pharmaceutical INC. | $35.22 | 2020-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $23.44 | 2025 | Gomekli |
| Glaxosmithkline, LLC. | $23.20 | 2020 | |
| Aucta Pharmaceuticals, INC. | $20.54 | 2025 | Motpoly Xr |
| Alexion Pharmaceuticals, INC. | $18.30 | 2025 | Koselugo |
| Amphastar Pharmaceuticals, INC. | $16.71 | 2024 | Baqsimi |
| Sobi, INC | $14.47 | 2019 | |
| Uswm, LLC | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Mullick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.